[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100353124":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":29,"responsibleParty":101,"collaborators":103,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":10,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":10,"enrollmentInfo":116,"targetDuration":10,"studyType":119,"phases":10,"briefSummary":120,"conditions":121,"keywords":10,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Allarity Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ovarian cancer patients",null,"with formalin-fixed paraffin-embedded (FFPE) tumor tissue available",[13],"Device: Drug Response Predictor® (DRP)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Drug Response Predictor® (DRP)","A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"US: Kathleen Moore","CONTACT","+1 405-271-8707","KathleenMoore@ouhealth.com",{"name":27,"role":23,"phone":10,"phoneExt":10,"email":28},"Europe: Rebecca Kristeleit","Rebecca.Kristeleit@gstt.nhs.uk",[30,44,63,80,93],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":10},"Dana-Farber Cancer Institute","COMPLETED","Boston","Massachusetts","02215","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-71.05977,42.35843,{"lat":42,"lon":41},{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":36,"countryCode":37,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"OU Health Stephenson Cancer Center","RECRUITING","Oklahoma City","Oklahoma","73104",{"type":39,"coordinates":51},[52,53],-97.51643,35.46756,{"lat":53,"lon":52},[56,60],{"name":57,"role":23,"phone":58,"phoneExt":10,"email":59},"Christine Pappaterra, RN","405-271-8707","Christine-Pappaterra@ouhsc.edu",{"name":61,"role":62,"phone":10,"phoneExt":10,"email":10},"Kathleen Moore, MD","PRINCIPAL_INVESTIGATOR",{"facility":64,"status":46,"city":65,"state":66,"zip":67,"country":36,"countryCode":37,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Swedish Center for Research and Innovation","Seattle","Washington","98122",{"type":39,"coordinates":69},[70,71],-122.33207,47.60621,{"lat":71,"lon":70},[74,78],{"name":75,"role":23,"phone":76,"phoneExt":10,"email":77},"Karina Sills","206-386-2227","karina.sills@swedish.org",{"name":79,"role":62,"phone":10,"phoneExt":10,"email":10},"Fernanda Baptista Musa, MD",{"facility":81,"status":82,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":92,"contacts":10},"Beatson West of Scotland Cancer Centre","ACTIVE_NOT_RECRUITING","Glasgow","Scotland","G12 0YN","United Kingdom","UK",{"type":39,"coordinates":89},[90,91],-4.25763,55.86515,{"lat":91,"lon":90},{"facility":94,"status":82,"city":95,"state":10,"zip":10,"country":86,"countryCode":87,"cosmosGeoPoint":96,"geoPoint":100,"contacts":10},"Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital","London",{"type":39,"coordinates":97},[98,99],-0.12574,51.50853,{"lat":99,"lon":98},{"type":102,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[104],{"name":105,"class":106},"Amarex Clinical Research","OTHER","100353124","clinical-pre-screening-protocol-for-ovarian-cancer-100353124",false,"NCT03877796","Clinical Pre-screening Protocol for Ovarian Cancer","Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer","Inclusion Criteria:\n\n* Patients with histological confirmed epithelia ovarian cancer\n* Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.\n* Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting\n* FFPE tumor tissue available\n\nExclusion Criteria:\n\n* Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.\n* Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator","FEMALE","18 Years",{"count":117,"type":118},60,"ESTIMATED","OBSERVATIONAL","The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.",[122],"Ovarian Cancer","2025-10-28",{"date":125,"type":126},"2025-10-30","ACTUAL",{"date":128,"type":126},"2019-04-11",{"date":130,"type":118},"2026-12",{"name":5,"class":6},5]